PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
PROCEPT BioRobotics to Present at Upcoming 2024 Leerink Partners Healthcare Crossroads Conference and 44th Annual William Blair Growth Stock Conference
SAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas. Management is scheduled to present on Wednesday, May 29 at 10:20 a.m. Eastern Time. Additionally, members of management will present at the upcoming 44th Annual William Blair Growth Stock Conference in Chicago. Management is scheduled to present on Tuesday, June 4 at 5:00 p.m. Eastern Time.
加利福尼亚州圣何塞，2024 年 5 月 13 日（环球新闻专线）— PROCEPT BioRobotics 纳斯达克股票代码：PRCT）（“公司”）是一家专注于通过开发泌尿外科变革性解决方案来促进患者护理的外科机器人公司。该公司今天宣布，管理层成员将出席即将在德克萨斯州奥斯汀举行的2024年Leerink Partners医疗保健十字路口会议。管理层定于美国东部时间5月29日星期三上午10点20分发表演讲。此外，管理层成员将出席即将举行的44届会议第四 在芝加哥举行的年度威廉·布莱尔成长股票会议。管理层定于美国东部时间6月4日星期二下午 5:00 发表讲话。
A live webcast of each event, as well as an archived recording, will be available on the "Investors" section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after the event.
每场活动的网络直播以及存档录音将在公司网站的 “投资者” 栏目上提供，网址为： https://ir.procept-biorobotics.com。网络直播将在活动结束后至少 90 天内存档并可供重播。
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
关于 PROCEPT BioRobotics 公司
PROCEPT BioRobotics是一家手术机器人公司，致力于通过开发泌尿科变革性解决方案来促进患者护理。PROCEPT BioRobotics开发、制造和销售AquaBeam机器人系统，这是一种先进的图像引导手术机器人系统，用于微创泌尿外科手术，最初的重点是治疗良性前列腺增生（BPH）。良性前列腺增生是最常见的前列腺疾病，在美国影响约4000万男性。PROCEPT BioRobotics 设计的水消融疗法旨在为因良性前列腺增生引起的下尿路症状或 LUTS 的男性提供有效、安全和持久的疗效，这些症状与前列腺大小和形状或外科医生的经验无关。该公司已经开发了大量且不断增长的临床证据，其中包括九项临床研究和150多份经过同行评审的出版物，这些证据支持了Aquablation疗法的益处和临床优势。
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com
投资者联系人：
Matt Bacso
投资者关系和业务运营副总裁
m.bacso@procept-biorobotics.com
译文内容由第三方软件翻译。